Cost-Effectiveness of Abatacept, Tocilizumab and TNF-inhibitors Compared With Rituximab as Second-Line Biologic Drug in Rheumatoid Arthritis

PLoS ONE - United States
doi 10.1371/journal.pone.0220142
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)